NDAORALTABLET
Approved
May 2009
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19
Data completeness
7/8 — Comprehensive
FANAPT (iloperidone) by Vanda Pharmaceuticals is unknown. Approved for schizophrenia. First approved in 2009.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FANAPT (iloperidone) is an oral atypical antipsychotic tablet approved by the FDA in May 2009 for the treatment of schizophrenia. The drug's mechanism is believed to involve dopamine D2 and serotonin 5-HT2 antagonism, with an active metabolite (P88) that shares a similar receptor binding profile. FANAPT occupies a niche position in the atypical antipsychotic market, competing primarily against long-acting injectables and newer mechanisms of action.
$0.1BPart D
5.6 years to LOEMechanism of Action
unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.
Pharmacologic Class:
Atypical Antipsychotic
Indications (1)
Clinical Trials (19)
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Started Sep 2025
240 enrolled
HypertensionUncontrolled Hypertension
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Started Jul 2024
26 enrolled
SchizophreniaBipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Started May 2023
100 enrolled
SchizophreniaBipolar I Disorder
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Started Jun 2022
0Parkinson Disease Psychosis
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Started Jun 2021
25 enrolled
Healthy
Worked on FANAPT at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.